Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation
Source abstract
Abstract
Immunologically “cold” tumors, characterized by low immune cells infiltration, represent a significant obstacle to the success of immune checkpoint therapy. Intestinal microbiome therapy has emerged as a potential strategy to overcome this challenge by reprogramming the immune microenvironment. However, its clinical application is constrained by unresolved safety concerns. To address these challenges, we fused Escherichia coli -secreted outer membrane vesicle (OMV) with the macrophage membrane vector (RV) to construct hybrid nanovesicle (ROMV) and encapsulated the bacterial metabolite trimethylamine N -oxide (TMAO), forming ROMV/TMAO. ROMV/TMAO mimicked the beneficial functions of intestinal probiotics by leveraging the immunomodulatory properties of OMV and TMAO, combined with the tumor-homing capabilities of RV. In human lung cancer organoids and multiple tumor models, selective tumor targeting and accumulation of ROMV/TMAO facilitated M1 polarization of tumor-associated macrophages and enhanced CD8 + T lymphocyte infiltration, ultimately inhibiting tumor growth. When combined with ROMV/TMAO, the immune checkpoint inhibitor α-PD-L1 exhibited superior antitumor efficacy than monotherapy. This study introduces a probiotic-inspired nanotherapeutic strategy for augmenting immune checkpoint therapy outcomes while addressing microbiome therapy safety challenges. probiotic-inspired nanomaterials for augmenting immune checkpoint therapy (ICT) outcomes while addressing microbiome therapy safety challenges. • A probiotic-inspired nanotherapeutic strategy for augmenting immune checkpoint therapy outcomes. • Tumor targeting of ROMV/TMAO facilitates M1 polarization of macrophages and enhances CD8 + T cells infiltration. • ROMV/TMAO significantly enhances Anti -PD-L1 therapy efficacy in human lung cancer organoids and multiple tumor models.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Advances in cancer immunotherapies10.1016/j.cell.2023.02.039 ↗
2. Immune-related adverse events associated with immune checkpoint blockade10.1056/NEJMra1703481 ↗
3. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
4. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models10.1126/scitranslmed.aba9772 ↗
5. Immune checkpoint Therapy—Current perspectives and future directions10.1016/j.cell.2023.03.006 ↗
6. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer10.1038/s41571-019-0281-6 ↗
7. ARIH1 activates STING-Mediated T-cell activation and sensitizes tumors to immune checkpoint blockade
8. Innate and adaptive immune cells in the tumor microenvironment10.1038/ni.2703 ↗
9. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade10.1016/j.cell.2021.09.020 ↗
10. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients10.1126/science.abb5920 ↗
11. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor10.1016/j.chom.2024.06.010 ↗
12. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
13. Boosting immune checkpoint therapy efficacy of pancreatic cancer by cell‐anchoring probiotic10.1002/adfm.202502197 ↗
14. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy10.1038/s41392-022-01304-4 ↗
15. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment10.1016/j.cell.2023.03.011 ↗
16. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy10.1126/science.abc3421 ↗
17. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer10.1016/j.cmet.2022.02.010 ↗
18. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer10.1126/sciimmunol.abn0704 ↗
19. Roseburia intestinalisgenerated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+T cells10.1136/gutjnl-2023-330291 ↗
20. Composition and functions of bacterial membrane vesicles10.1038/s41579-023-00875-5 ↗
21. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity10.1038/s41565-023-01553-6 ↗
22. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy
23. Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy10.1038/s41467-023-38679-z ↗
24. Microbiota: a key factor affecting and regulating the efficacy of immunotherapy10.1002/ctm2.1508 ↗
25. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies10.1186/s13045-022-01273-9 ↗
26. Role of the microbiota in response to and recovery from cancer therapy10.1038/s41577-023-00951-0 ↗
27. Exploiting bacteria for cancer immunotherapy10.1038/s41571-024-00908-9 ↗
28. Engineered bacterial outer membrane vesicles as controllable two‐way adaptors to activate macrophage phagocytosis for improved tumor immunotherapy10.1002/adma.202206200 ↗
29. Systemic tumor suppression via macrophage-driven automated homing of metal-phenolic-gated nanosponges for metastatic melanoma10.1002/advs.202207488 ↗
30. Hybrid-membrane-decorated prussian blue for effective cancer immunotherapy via tumor-associated macrophages polarization and hypoxia relief10.1002/adma.202200389 ↗
31. NaCl enhances CD8+ T cell effector functions in cancer immunotherapy10.1038/s41590-024-01923-9 ↗
32. A dietary commensal microbe enhances antitumor immunity by activating tumor macrophages to sequester iron10.1038/s41590-024-01816-x ↗
33. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles10.1038/s41467-020-20723-x ↗
34. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer10.1126/scitranslmed.adj9366 ↗
35. CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages10.7150/thno.29617 ↗
36. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data10.1038/s41568-021-00418-1 ↗
37. Pancreatic cancer: advances and challenges10.1016/j.cell.2023.02.014 ↗
38. Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids10.1038/s41551-023-01156-5 ↗
39. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment10.1038/s41568-024-00706-6 ↗
40. Patient-derived organoids in precision cancer medicine
41. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice10.1038/s41564-020-00831-6 ↗
42. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients10.1126/science.aan4236 ↗
43. Targeting the gut and tumor microbiota in cancer
44. Macrophages as tools and targets in cancer therapy10.1038/s41573-022-00520-5 ↗
45. Engineered bacterial biomimetic vesicles reprogram tumor-associated macrophages and remodel tumor microenvironment to promote innate and adaptive antitumor immune responses10.1021/acsnano.3c06987 ↗
46. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer10.1038/s41467-021-24331-1 ↗
47. Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy10.1038/s41467-023-40439-y ↗
48. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of cre recombinase10.1038/nprot.2009.95 ↗
49. Kindlin-2 links mechano-environment to proline synthesis and tumor growth10.1038/s41467-019-08772-3 ↗
50. PINCH-1 regulates mitochondrial dynamics to promote proline synthesis and tumor growth10.1038/s41467-020-18753-6 ↗
51. STAR: ultrafast universal RNA-seq aligner10.1093/bioinformatics/bts635 ↗
52. Integrating single-cell transcriptomic data across different conditions, technologies, and species10.1038/nbt.4096 ↗
53. Integrated analysis of multimodal single-cell data10.1016/j.cell.2021.04.048 ↗
54. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage10.1038/s41590-018-0276-y ↗